NWMG
ACAD icon

National Wealth Management Group’s Acadia Pharmaceuticals ACAD Stock Holding History

National Wealth Management Group’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-21,733
Closed -$469K – 229
2025
Q2 		$469K Buy
21,733
+1,987
+10% +$36.9K 0.26% 91
2025
Q1 		$328K Buy
+19,746
New +$359K 0.22% 108

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

National Wealth Management Group's ACAD Position: Q3 2025 in Review

National Wealth Management Group sold out of Acadia Pharmaceuticals (ACAD) in Q3 2025, closing a stake of 21,733 shares — an estimated $469K sold.

National Wealth Management Group first reported a position in ACAD in Q1 2025 and held it in 2 quarters. The position peaked at $469K in Q2 2025. 334 funds tracked by Wall St. Rank hold ACAD as of Q3 2025.

  • National Wealth Management Group reported no remaining Acadia Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • National Wealth Management Group sold 21,733 Acadia Pharmaceuticals shares in Q3 2025, an estimated $469K.
  • National Wealth Management Group first reported a position in Acadia Pharmaceuticals in Q1 2025 and held it in 2 quarters.
  • National Wealth Management Group's Acadia Pharmaceuticals position peaked at $469K in Q2 2025.
  • 334 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2025.

Based on National Wealth Management Group's 13F filing for Q3 2025, filed 31 Oct 2025.